Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06759649 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
A Phase 1 study of Neoplasm and Cancer, Malignant Tumors, sponsored by Compugen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 11
- Study locations
NCT06759649: Recruiting Phase 1 study of Neoplasm and Cancer, Malignant Tumors, sponsored by Compugen.
NCT06759649 is a Phase 1 study of Neoplasm and Cancer, Malignant Tumors that is actively recruiting participants, run by Compugen. The registered enrollment target is 200 participants, roughly in line with the 184-participant average among 11 other Neoplasm trials with a reported enrollment target. The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06759649, a Phase 1 study of Neoplasm and Cancer, Malignant Tumors, is actively recruiting participants, sponsored by Compugen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 11
- Study locations
Study Summary
The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.
Primary Outcome
Number of participants in monotherapy cohorts with treatment-related adverse events as assessed by CTCAE v4.0
Conditions Studied
Interventions
- DRUG Zimberelimab
- DRUG COM503
Study Locations (11)
Israel
- Rambam Health Care Campus - Haifa
- Hadassah University Medical Center- Ein Kerem - Jerusalem
- Rabin Medical Center - Petah Tikva
- The Chaim Sheba Medical Center - Ramat Gan
Texas
- NEXT Oncology San Antonio - San Antonio
- START - San Antonio
Connecticut
- Yale- New Haven Hospital- Yale Cancer Center - New Haven
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- START Midwest - Grand Rapids
Tennessee
- The West Clinic, PLCC dba West Cancer Center - Germantown
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2027-11-22 |
| Phase | Phase 1 |
What NCT06759649 shows while recruiting
NCT06759649 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 184-participant average among 11 other Neoplasm trials with a reported enrollment target.
The record links to 2 conditions, with Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.
NCT06759649 lists 11 locations in 7 states (Israel, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06759649 about?
NCT06759649 is a clinical study titled "A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies". The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM50...
What is the current status of trial NCT06759649?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2025-01-07. Estimated completion is 2027-11-22.
What conditions does trial NCT06759649 study?
This clinical trial studies the following conditions: Neoplasm, Cancer, Malignant Tumors.
What interventions are being tested in trial NCT06759649?
The interventions under investigation include: Zimberelimab (DRUG), COM503 (DRUG).
Who is sponsoring clinical trial NCT06759649?
This trial is sponsored by Compugen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06759649 being conducted?
This trial has 11 study locations across Connecticut, Massachusetts, Michigan, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06759649's enrollment target sits among peer trials
200 3rd of 11 higher than 9 of 11 other Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY2835219 in Participants With Cancer
COMPLETED · Phase 1
-
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
COMPLETED · Phase 1
-
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
COMPLETED · Phase 1
-
A Study of Galunisertib on the Immune System in Participants With Cancer
COMPLETED · Phase 1
-
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI